Executive Summary
On July 24, 2026, a wave of 16 regulatory filings revealed a surge in trading suspension and delisting risks across US-listed companies, predominantly driven by non-compliance with Nasdaq's $1.00 minimum bid price rule.
A staggering 13 of 16 filings involve bid price deficiencies, with several companies receiving their second notice within a year, indicating a systemic failure to maintain share price thresholds. The cluster of filings on a single day suggests a coordinated exchange review cycle, creating a concentrated risk event for investors holding these securities. While most companies have 180-day cure periods, the high recurrence rate and ineligibility for extensions due to prior reverse splits (e.g., FibroBiologics) signal a 'penalty box' dynamic where serial non-compliers face accelerated delisting. The only voluntary delisting (Trinity Capital) and the sole equity-based deficiency (VivoSim Labs) stand as outliers, highlighting that the primary systemic risk is price-driven, not fundamental. The lack of any bullish or positive insider activity across all filings reinforces a uniformly negative sentiment, with management teams scrambling for reverse splits as a last-resort remedy.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from July 16, 2026.
Investment Signals (9)
- VivoSim Labs ↓ (BULLISH)▲
Received a delisting notice for negative equity but subsequently raised ~$14.1M through a milestone payment, private placement, and warrant exercises, bringing equity back above $2.5M. This rapid capital infusion creates a high-probability compliance path, with a September 3 deadline to submit a plan.
- Chegg ↓ (BEARISH)▲
Received its SECOND NYSE bid price deficiency notice in seven months (first in Dec 2025, cured by May 2026). This recurrence pattern signals structural business deterioration and a high likelihood of eventual delisting if a reverse split is not executed.
- FibroBiologics ↓ (BEARISH)▲
Ineligible for the standard 180-day compliance period due to a reverse stock split within the prior year. With a July 29 appeal deadline and a potential suspension as early as July 31, this is the most time-critical delisting event in the batch.
- Trinity Capital ↓ (BEARISH)▲
Voluntarily delisting all three classes of securities (common stock and two note series) from Nasdaq, citing no regulatory action. This move destroys liquidity for shareholders and noteholders, suggesting a strategic exit from public markets or a going-private transaction.
- GoPro ↓ (BEARISH)▲
Received a Nasdaq bid price deficiency notice on July 21. As a well-known consumer brand with a 180-day cure period, the market will closely watch for a reverse split announcement or operational turnaround to avoid delisting.
- Odyssey Marine Exploration ↓ (BULLISH)▲
Has shareholder-approved reverse split authority (1:20 to 1:25) from June 1, 2026, providing a clear and executable path to compliance ahead of its merger with AOM. This pre-authorized remedy reduces delisting risk relative to peers.
- Surf Air Mobility ↓ (MIXED)▲
Received a NYSE deficiency notice on the same day shareholders approved a reverse stock split (2:1 to 6:1). The concurrent approval provides a near-term catalyst to cure the deficiency, but the split's dilutive impact is a negative for existing holders.
- Liminatus Pharma ↓ (BEARISH)▲
Has exhausted its initial 180-day compliance period (ended July 14) and is now at the Nasdaq Hearings Panel stage, with a written response due July 27. This is the most advanced-stage delisting case, with the highest probability of imminent suspension.
- Fusemachines ↓ (BEARISH)▲
Deficient in Market Value of Publicly Held Shares (MVPHS) rather than bid price, a less common but equally serious deficiency. The company has 180 days to cure, but the underlying cause—low share price and float—may require a reverse split or capital raise.
Risk Flags (8)
- FibroBiologics/Imminent Suspension↓ [HIGH RISK]▼
The company faces a potential trading suspension as early as July 31, 2026, if it fails to request a hearing by July 29. This is the highest-risk event in the batch, with a 2-day window for action.
- Liminatus Pharma/Advanced Delisting↓ [HIGH RISK]▼
Already past the initial compliance period, with a Hearings Panel decision pending. The company must submit its views by July 27, and failure to secure an extension will result in immediate delisting.
- Chegg/Recurrence Pattern↓ [HIGH RISK]▼
The second deficiency notice in seven months indicates that the prior cure (likely a reverse split or price spike) was temporary. This structural failure suggests the business model is under secular pressure from AI alternatives.
- Trinity Capital/Liquidity Destruction↓ [HIGH RISK]▼
Voluntary delisting of all securities will severely reduce liquidity for existing holders, potentially triggering forced selling by institutional investors with exchange-listing mandates.
- Invivyd/No Assurance of Cure↓ [MEDIUM RISK]▼
The filing explicitly states 'no assurance' of regaining compliance, with a January 2027 deadline. The lack of a disclosed remedy plan (e.g., reverse split authorization) increases uncertainty.
- Standard BioTools/No Disclosed Remedy↓ [MEDIUM RISK]▼
While the company intends to work toward compliance, no specific plan (reverse split, capital raise) has been disclosed, leaving the path to cure undefined.
- Peraso/Compressed Timeline↓ [MEDIUM RISK]▼
The 2026 Annual Meeting is set for September 10, with a stockholder proposal deadline of August 3. If a reverse split requires shareholder approval, the timeline for action is tight.
- Quantum-Si/Transfer Dependency↓ [MEDIUM RISK]▼
The company may need to transfer to the Nasdaq Capital Market to qualify for an additional 180-day period, which requires payment of an application fee and written notice. Failure to execute this transfer could shorten the cure window.
Opportunities (8)
- VivoSim Labs/Capital Infusion Catalyst↓ (OPPORTUNITY)◆
The company has already resolved its equity deficiency through a $5M milestone payment, $4M private placement, and $5.1M warrant exercises. With a clear path to compliance and a September 3 deadline, the stock could re-rate as delisting risk recedes.
- Odyssey Marine Exploration/Pre-Authorized Reverse Split↓ (OPPORTUNITY)◆
With shareholder approval already in hand for a 1:20 to 1:25 reverse split, the company can execute a cure quickly without the delay of a shareholder vote. The upcoming merger with AOM provides an additional catalyst.
- Surf Air Mobility/Concurrent Cure and Split↓ (OPPORTUNITY)◆
The shareholder-approved reverse split (2:1 to 6:1) on the same day as the NYSE notice provides a near-term catalyst to cure the deficiency. If executed promptly, the stock could stabilize.
- GoPro/Brand Recovery Play↓ (OPPORTUNITY)◆
As a well-known brand, GoPro has options beyond a reverse split, including operational improvements or a strategic transaction. The 180-day window provides time for a turnaround story to emerge.
- Chegg/Short Squeeze Potential↓ (OPPORTUNITY)◆
With a second deficiency notice in seven months, the stock is likely heavily shorted. Any positive news (e.g., AI partnership, reverse split announcement) could trigger a short squeeze.
- Trinity Capital/Going-Private Premium↓ (OPPORTUNITY)◆
The voluntary delisting may precede a take-private transaction or tender offer. Investors who hold through the delisting could receive a premium if a buyout materializes.
- Fusemachines/MVPHS Cure via Price Appreciation↓ (OPPORTUNITY)◆
Unlike bid price deficiencies, MVPHS can be cured by share price appreciation alone, without a reverse split. If the company announces positive news, the market value could recover organically.
- LiqTech International/Additional Extension Eligibility↓ (OPPORTUNITY)◆
The company may qualify for a second 180-day compliance period if it meets other listing standards, providing a longer runway than peers. This reduces immediate delisting pressure.
Sector Themes (5)
- Bid Price Deficiency Epidemic◆
13 of 16 filings (81%) involve failure to maintain the $1.00 minimum bid price, indicating a broad market phenomenon of low-priced stocks under regulatory scrutiny. This cluster suggests a systematic review by exchanges, not isolated events.
- Recurrence and Serial Non-Compliance◆
Chegg and FibroBiologics highlight a pattern where companies receive multiple deficiency notices within a year, often after a reverse split fails to provide a lasting cure. This 'revolving door' dynamic signals structural business weakness.
- Reverse Split as a Double-Edged Sword◆
While reverse splits are the primary remedy (Odyssey, Surf Air, Liminatus), they often lead to further price declines and ineligibility for future extensions (FibroBiologics). Investors should view reverse splits as a temporary fix, not a solution.
- Concentration in Micro-Cap and Biotech◆
The affected companies are predominantly micro-cap (VivoSim, Fusemachines, Peraso) or pre-revenue biotech (FibroBiologics, Oncolytics, Invivyd), sectors already characterized by high volatility and low liquidity. Delisting risk amplifies existing investment risks.
- Voluntary Delisting as a Strategic Exit◆
Trinity Capital's voluntary delisting of all securities is a rare event that may signal a broader trend of companies choosing to exit public markets to avoid compliance costs and regulatory burden, particularly for BDCs and small-cap financials.
Watch List (8)
-
The company must request a hearing by July 29, 2026, to stay the delisting. Failure to do so will result in suspension on July 31. This is the most time-sensitive event in the batch.
-
The company must submit its written response by July 27, 2026. The Panel's decision on continued listing will determine the stock's fate. Watch for a ruling within days of the submission.
-
With a six-month cure period starting July 24, 2026, watch for any announcement of a reverse split or business restructuring. The stock's price action in the first 30 days will signal market confidence.
-
The company has until September 3, 2026, to submit a plan to Nasdaq. Approval of the plan and a potential 180-day extension (until Jan 2027) would be a positive catalyst.
-
With shareholder approval in hand, watch for the company to announce the specific ratio and effective date of the reverse split. Execution before the January 2027 deadline is expected.
-
The board has authority for a 2:1 to 6:1 split. Watch for the specific ratio and timing, as a higher ratio (6:1) would be more dilutive but provide a larger buffer against future deficiencies.
-
After the July 24 delisting, watch for any announcement of a tender offer, going-private transaction, or OTC listing. The stock's liquidity and price discovery will be severely impacted.
- General Market/Broader Delisting Wave👁
The concentration of filings on July 24 may indicate a broader exchange review. Watch for additional deficiency notices from other low-priced stocks in the coming weeks, which could signal a market-wide trend.
Filing Analyses
(16)
24-07-2026
VivoSim Labs received a Nasdaq delisting notice on July 20, 2026, for failing to meet the minimum $2.5M stockholders' equity requirement under Listing Rule 5550(b)(1), as its Annual Report showed negative equity of $(1,099,000). However, subsequent transactions—including a $5.0M milestone payment from Eli Lilly, a $4.0M private placement, and the exercise of warrants adding ~$5.1M to equity—have brought stockholders' equity back above $2.5M as of the filing date. The company has until September 3, 2026 to submit a compliance plan, and its stock remains listed on Nasdaq under 'VIVS' for now.
- · The company has 45 calendar days from July 20, 2026 (until September 3, 2026) to submit a compliance plan to Nasdaq.
- · If Nasdaq accepts the plan, it may grant an extension of up to 180 calendar days (until January 16, 2027) to regain compliance.
- · If the plan is not accepted, the company has the right to appeal to a Nasdaq hearings panel.
- · The private placement closed on July 17, 2026, with a combined purchase price of $0.85 per share/pre-funded warrant and accompanying common warrant.
- · The company's common stock continues to trade on the Nasdaq Capital Market under symbol 'VIVS' with no immediate effect on listing.
24-07-2026
Invivyd, Inc. received a Nasdaq deficiency letter on July 23, 2026, because its common stock (IVVD) closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until January 19, 2027 to regain compliance, with a potential second compliance period if it transfers to the Nasdaq Capital Market. There is no assurance that Invivyd will be able to cure the deficiency, and failure could lead to delisting.
- · The deficiency letter was received on July 23, 2026, and the filing was made on July 24, 2026.
- · The company's common stock has a par value of $0.0001 per share.
- · The initial compliance period ends on January 19, 2027.
- · If the company does not regain compliance by that date, it may be eligible for a second 180-day compliance period by transferring to the Nasdaq Capital Market.
- · The company intends to monitor the bid price and consider options, but there is no assurance of regaining compliance.
24-07-2026
FibroBiologics, Inc. received a Staff Determination letter from Nasdaq on July 22, 2026, notifying the company that its securities will be delisted from The Nasdaq Capital Market due to non-compliance with the minimum bid price rule (closing bid price below $1.00 per share for 30 consecutive business days). The company is not eligible for the standard 180-day compliance period because it effected a reverse stock split within the prior year. FibroBiologics intends to appeal the determination by requesting a hearing before a Nasdaq Hearings Panel, which will stay the delisting pending the hearing process, but there is no assurance of success.
- · The delisting determination was based on the bid price closing below $1.00 per share from June 8, 2026 through July 21, 2026.
- · The company must request an appeal by July 29, 2026 to stay the delisting; otherwise, suspension will begin at the opening of business on July 31, 2026.
- · The company is ineligible for the 180-day compliance period due to a reverse stock split effected within the prior one-year period.
24-07-2026
Trinity Capital Inc. has voluntarily filed a Form 25 with the SEC to delist its common stock and two series of 7.875% Notes (due March 2029 and September 2029) from The Nasdaq Stock Market, effective July 24, 2026. The delisting is a voluntary withdrawal by the issuer and not a result of regulatory or exchange action. This move will reduce liquidity and market access for existing shareholders and noteholders.
- · The delisting covers all three classes of securities: common stock and two series of notes.
- · The filing cites 17 CFR 240.12d2-2(c) for voluntary withdrawal, not a forced delisting.
- · No financial details or reasons for the delisting are provided in the filing.
24-07-2026
Chegg, Inc. received a NYSE notice on July 24, 2026 for non-compliance with the minimum share price requirement (average closing price below $1.00 over 30 consecutive trading days). This is the second such notice, following a prior notice in December 2025 that was cured by end of May 2026. The company has a six-month cure period and may consider a reverse stock split, but faces potential delisting if it fails to regain compliance.
- · The prior NYSE notice from December 2025 was cured by end of May 2026, but the company has now fallen out of compliance again.
- · The company can regain compliance if on the last trading day of any calendar month during the six-month cure period the closing price is at least $1.00 and the 30-trading-day average is at least $1.00.
- · The notice has no immediate impact on listing; shares continue to trade on NYSE during the cure period.
24-07-2026
GoPro, Inc. received a notice from Nasdaq on July 21, 2026, stating that its Class A common stock has failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Listing Rule 5450(a)(1). The company has a 180-calendar-day grace period to regain compliance by achieving a closing bid price of at least $1.00 for ten consecutive business days. The notice does not immediately affect the listing or trading of GPRO shares on the Nasdaq Global Select Market.
- · The minimum bid price threshold is $1.00 per share.
- · The company must maintain a closing bid price of $1.00 or more for at least ten consecutive business days during the 180-day period to regain compliance.
- · The notice was received on July 21, 2026, and the 8-K was filed on July 24, 2026.
- · The company's Class A common stock trades under the symbol GPRO on the Nasdaq Global Select Market.
24-07-2026
Standard BioTools Inc. (LAB) received a Nasdaq notice on July 22, 2026, for failing to meet the $1.00 minimum bid price requirement over 30 consecutive business days. The company has a 180-day compliance period until January 19, 2027, to regain compliance, and its stock continues to trade uninterrupted. While the company intends to work toward restoring compliance, there is no assurance it will succeed, and a potential transfer to the Nasdaq Capital Market or a reverse stock split may be necessary.
- · The company has 180 calendar days, until January 19, 2027, to regain compliance with the minimum bid price requirement.
- · To regain compliance, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days.
- · If the company meets all other continued listing standards, it may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
- · The company may need to implement a reverse stock split to cure the deficiency.
- · The notice has no immediate effect on trading or business operations.
24-07-2026
Arrive AI Inc. received a Nasdaq notification on July 21, 2026, for failing to meet the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $15 million for 32 consecutive business days. The stock continues to trade under 'ARAI' with no immediate effect, but the company has 180 days (until January 19, 2027) to regain compliance or face potential delisting. While the company intends to monitor and pursue compliance options, the notification highlights ongoing market value weakness.
- · Non-compliance was specifically with Nasdaq Listing Rule 5450(b)(2)(C) for minimum MVPHS of $15 million.
- · The non-compliance period ran from June 3, 2026 to July 20, 2026 (32 consecutive business days).
- · The cure period ends on January 19, 2027; if not met, Nasdaq will issue a delisting notification.
- · An alternative option is applying for a transfer to The Nasdaq Capital Market, subject to meeting continued listing requirements.
- · The company's common stock par value is $0.0002 per share.
24-07-2026
Odyssey Marine Exploration received a Nasdaq deficiency notice on July 21, 2026, for failing to maintain a minimum bid price of $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2). The company has a 180-day cure period ending January 19, 2027, and plans to regain compliance via a reverse stock split (1-for-20 to 1-for-25) approved by stockholders on June 1, 2026, ahead of its merger with American Ocean Minerals Corporation. While the notice has no immediate delisting impact, failure to cure could lead to delisting, and the company's stock price remains below $1.00, reflecting ongoing financial distress.
- · Stockholders approved a reverse stock split on June 1, 2026, at a ratio between 1-for-20 and 1-for-25.
- · The company expects the reverse stock split to enable compliance before the merger with AOM closes.
- · If not compliant by January 19, 2027, the company may qualify for an additional 180-day period if it meets other listing standards.
- · The merger with AOM was previously disclosed on April 8, 2026.
24-07-2026
Oncolytics Biotech Inc. received a Nasdaq deficiency letter on July 20, 2026, for failing to maintain a minimum bid price of $1.00 per share over 30 consecutive business days, triggering potential delisting. The company has a 180-day compliance period (until January 19, 2027) to regain compliance, and may qualify for an additional 180-day extension if certain conditions are met. The company is assessing options, but there is no assurance it will regain compliance or avoid delisting.
- · Letter received on July 20, 2026, from Nasdaq Listing Qualifications Staff.
- · Stock trades under symbol 'ONCY' on the Nasdaq Capital Market.
- · If compliance is regained during the Compliance Period, Nasdaq will confirm in writing.
- · For an additional 180-day period, the company must meet the market value of publicly held shares requirement and all other initial listing standards except the minimum bid price.
- · If the company is not eligible or cannot cure the deficiency, the stock will be subject to delisting.
24-07-2026
Liminatus Pharma, Inc. disclosed it has not regained compliance with Nasdaq's minimum bid price rule ($1.00) and is not eligible for a second 180-day extension. The Nasdaq Hearings Panel will decide on continued listing, with the company required to submit its views by July 27, 2026. The company is also seeking shareholder approval for a reverse stock split at its August 3, 2026 annual meeting as a potential remedy.
- · The company received the initial non-compliance notice on January 15, 2026, and the 180-day compliance period ended July 14, 2026.
- · A hearing before the Nasdaq Hearings Panel was held on June 30, 2026.
- · The company must submit its written response to the Panel regarding the additional deficiency by July 27, 2026.
- · The annual meeting of stockholders is scheduled for August 3, 2026, to authorize a reverse stock split.
24-07-2026
Fusemachines Inc. (FUSE) received a Nasdaq notification on July 24, 2026, for failing to maintain the minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 for the Nasdaq Global Market, as its MVPHS was below that threshold for 30 consecutive business days from June 10 to July 23, 2026. The company has 180 calendar days, until January 20, 2027, to regain compliance by closing at or above $15,000,000 for at least 10 consecutive business days. There is no immediate impact on listing or trading, and the company intends to evaluate options to regain compliance, though the outcome remains uncertain.
- · The non-compliance period for MVPHS was from June 10, 2026 through July 23, 2026.
- · The company's common stock continues to trade under the symbol 'FUSE' on the Nasdaq Global Market during the compliance period.
- · The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
24-07-2026
LiqTech International received a Nasdaq deficiency notice on July 21, 2026, for failing to maintain the $1 minimum bid price for 30 consecutive business days. The company has 180 calendar days, until January 19, 2027, to regain compliance by having the closing bid price meet or exceed $1.00 for at least ten consecutive business days. While the stock continues to trade under the symbol "LIQT" for now, failure to cure could lead to delisting, though an additional 180-day compliance period may be available if certain conditions are met.
- · The deficiency notice was received on July 21, 2026, and the filing was made on July 24, 2026.
- · The stock continues to trade on The Nasdaq Capital Market under the symbol "LIQT" with no immediate effect on listing.
- · If the company does not qualify for or fails to cure during the second 180-day compliance period, Nasdaq will notify the company of its determination to delist, with an opportunity to appeal to a Hearings Panel.
- · The company is considering its options to regain compliance but has not specified any concrete plan.
24-07-2026
Peraso Inc. (PRSO) received a Nasdaq deficiency notice on July 21, 2026, for failing to maintain a minimum bid price of $1 per share for 30 consecutive business days. The company has a 180-day cure period until January 19, 2027, and is considering options including a potential reverse stock split. Separately, the board set the 2026 Annual Meeting for September 10, 2026, with a stockholder proposal deadline of August 3, 2026.
- · Stockholders of record as of July 20, 2026 are entitled to vote at the 2026 Annual Meeting.
- · Stockholder proposals under Rule 14a-8 must be received by August 3, 2026.
- · Director nominations and other business outside Rule 14a-8 must also be submitted by August 3, 2026.
- · Universal proxy rule compliance notices are due by August 3, 2026.
24-07-2026
Surf Air Mobility Inc. received a notice from the NYSE on July 24, 2026, indicating non-compliance with the minimum average closing price of $1.00 over 30 consecutive trading days. The company has a six-month cure period to regain compliance. At the same time, shareholders approved a reverse stock split (ratio 2:1 to 6:1) to address the listing deficiency, and ratified PwC as auditor. However, the stock remains listed with no immediate impact on operations or SEC reporting.
- · The reverse stock split ratio ranges from 2:1 to 6:1, inclusive.
- · The company has 10 business days from receipt of the notice to notify NYSE of its intent to cure.
- · The cure period is six months following receipt of the notice.
- · To regain compliance, the company must have a closing share price of at least $1.00 on the last trading day of any calendar month during the cure period and an average closing price of at least $1.00 over the prior 30 trading days.
- · The notice has no immediate effect on the listing of the common stock.
24-07-2026
Quantum-Si Inc. received a Nasdaq notice on July 23, 2026, that its Class A common stock (QSI) has fallen below the $1.00 minimum bid price for 30 consecutive business days, failing the Bid Price Requirement for continued listing on The Nasdaq Global Market. The company has an initial 180-day compliance period until January 19, 2027, to regain compliance, and may be eligible for an additional 180-day period if it transfers to the Nasdaq Capital Market. There is no immediate impact on trading or operations, but failure to cure could lead to delisting.
- · The notice was received from the Listing Qualifications Department of Nasdaq.
- · The company may transfer to The Nasdaq Capital Market to qualify for an additional 180-day compliance period.
- · To effect a transfer, the company must pay an application fee and provide written notice of intent to cure, potentially via a reverse stock split.
- · If delisting is initiated, the company may appeal to a Nasdaq Hearings Panel, but success is not assured.
Get daily alerts with 9 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 16 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Trading Suspension Halt Orders
🇺🇸 More from United States
View all →July 17, 2026
US Pre-Market SEC Filings Roundup — July 17, 2026
US Pre-Market SEC Filings Roundup
July 17, 2026
USA Insider Trading Pulse — July 17, 2026
USA Insider Trading Pulse
July 17, 2026
US Merger & Acquisition SEC Filings — July 17, 2026
US Merger & Acquisition SEC Filings
July 16, 2026
US Pre-Market SEC Filings Roundup — July 16, 2026
US Pre-Market SEC Filings Roundup